DarioHealth Corp. (DRIO): debt financing — DarioHealth enters $32.5M credit agreement with Callodine; warrants issued

DarioHealth Corp.

Borrowed $32.5M at closing; may draw up to $17.5M more subject to revenue thresholds and lender discretion.
Loan bears interest at Term SOFR + 7.75%, matures April 2030; secured by substantially all assets.
Issued warrants to purchase 2,114,140 shares at $0.8278; up to $2.5M loan principal convertible at $0.9933 per share.
Prior Loan and Security Agreement with Avenue terminated; proceeds used to satisfy LSA.
Financial covenants include minimum unencumbered liquid assets, total revenue, and Adjusted EBITDA.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

DarioHealth Corp. incurred credit facility of $32.5 million with Callodine Commercial Finance, LLC at Term SOFR Rate plus 7.75% maturing April 2030.

Instrument: credit facility
Principal: $32.5 million
Counterparty: Callodine Commercial Finance, LLC
Rate: Term SOFR Rate plus 7.75%
Maturity: April 2030
Event: incurrence

Exact text from the filing

Under the terms of the Credit Agreement, each Lender agreed to make a multi-draw term loan to the Company (each a “Term Loan”) in which the Company borrowed $32.5 million at the time of closing on April 30, 2025.

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

DarioHealth Corp. filing history →

Source: SEC EDGAR

accession 0001104659-25-044809

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.